Then, the patient was given afatinib, and his condition has remained stable for 11 months.<h4>Conclusion</h4>Afatinib might be suitable for NSCLC-LM patients with EGFR compound mutations who show resistance to icotinib and osimertinib, since it might help overcome first- and third-generation TKI resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.